No Data
No Data
Veritas In Silico: Half Year Report - Term 9 (2024/01/01 - 2024/12/31)
List of stocks with maximum daily price increase or decrease during the morning session.
■Top Gainer: Veritas In Silico <190A>, Chordia Therapeutics <206A>, PRISM BioLab <2170>, Link and Motivation <2767>, Tsuburaya Fields Holdings <3260>, Espo <3551>, Dynic <3667>, Enish <3739>, Comseed <3798>, ULS Group <4575>, Canvas <4893>, Noel Immune Biotech.
Three key points to watch in the afternoon session: a weaker yen, a rise in semiconductor stocks, and a temporary recovery to the 36,000 yen level.
In the afternoon trading on the 13th, the following three points should be noted: - The Nikkei Average rebounded to the 36,000 yen level temporarily due to the depreciation of the yen and the rise of semiconductor stocks. - The USD/JPY was slightly up due to the sharp increase in Japanese stocks. - Top gainers were Toshiba Lighting & Technology Corp. <8035>, followed by Advantest Corp. <6857>. The Nikkei Average has surged significantly, rising by 760.55 yen (+2.17%) from the previous trading day, reaching 35,785.55 yen (volume...
Veritas In Silico: Fiscal year ending December 2024, 2nd quarter (interim) financial results presentation materials for the 9th period.
Veritas In Silico --- In the second quarter, drug discovery research with each partner in the mRNA-targeting small molecule drug discovery business is progressing smoothly.
Veritas In Silico <130A> announced its financial results for the second quarter of the fiscal year ending December 2024 (January to June 2024), with business revenue of 11.5 billion yen, operating loss of 6.6 billion yen, ordinary loss of 8.8 billion yen, and net loss of 9.0 billion yen. As we didn't prepare the quarterly financial statements for the interim period ended December 2023, we didn't describe the year-over-year changes for the interim period ending December 2024. In the mRNA targeted small molecule drug discovery business, we are engaged in drug discovery.
SOLIZE、Veritas In Silico
■SOLIZE <5871>: Estimated number of released shares: 4,050,000 (estimated) Release date: 06/08/2024 Target holders: Estimated employee shareholding association of SOLIZE Estimated number of shares: 1,326,600 Yukinori Furukawa: 754,800 shares Keiichi Shinohara: 300,000 shares Tokyo SME Investment & Growth, Inc.: 300,000 shares Maye Furukawa: 202,500 shares Yoshizumi Furukawa: 300,000 shares
No Data